Improving drug physical and chemical properties, delivery efficiency, enzymatic selectivity, stability and other properties through effective chemical structure modification.

Achieving targeted delivery to organs most relevant for treating a specific disease, resulting in the best balance between efficacy and safety.

Based on clinically validated active small molecules, we are capable of rapidly developing novel targeted prodrugs with significantly improved PK/PD and safety profile, therefore efficiently generating candidate compounds with high clinical value.

Prodrug-based approach has clear development advantages: shorter development cycle, lower cost, and much lower clinical failure risk. IP rights could also be achieved.

Capable of novel sequence design and modification of both oligonucleotides drugs and messenger RNA drugs.

An innovative chemical modification technology platform that can be applied toward differentiated design for target organs and improved PK/PD, efficacy and overall druggability of RNA therapeutics/oligonucleotides drugs.

Diversified advanced drug delivery technology, capable of selectively delivering drugs for liver and extrahepatic organs as well as systemic or local drug delivery mechanisms.